News

2022

Areteia Therapeutics named as one of the Most Promising Biotech Startups of 2022

Ian Read named Chairman of the Board of Areteia Therapeutics

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

2021

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Dexpramipexole Targets Eosinophilic Inflammation

2020

Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

Knopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series Aug. 18

2019

Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome

Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases

2018

NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases

2017

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes